3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
22
Neoplasms
20
Lung Neoplasms
10
Colorectal Neoplasms
8
Uterine Cervical Neoplasms
6
Papillomavirus Infections
5
Head and Neck Neoplasms
5
Fatigue
5
Multiple Myeloma
4
Lymphoma
4
Hematologic Neoplasms
4
Urinary Bladder Neoplasms
3
Skin Neoplasms
3
Prostatic Neoplasms
3
Melanoma
3
Hematopoietic and Lymphoid System Neoplasm
3
Gastrointestinal Neoplasms
3
Sleep Wake Disorders
2
Skin Cancer Prevention
2
Obesity
2
Neoplasm Metastasis
2
Motor Activity
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Hematopoietic and Lymphatic System Neoplasm
2
Diabetes Mellitus
2
Depression
2
Caregiver
2
Cancer Survivor
2
Interventions
Dexamethasone
5
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Blood Specimen Collection
4
Surveys and Questionnaires
3
Prednisone
3
Melphalan
3
Lenalidomide
3
Biopsy, Fine-Needle
3
fluciclovine F-18
2
carfilzomib
2
Positron-Emission Tomography
2
Mammography
2
Injections
2
Immunohistochemistry
2
Gemcitabine
2
Cytarabine
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
weifuchun
1
vistusertib
1
venetoclax
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
ricolinostat
1
pomalidomide
1
phosphoribosylformylglycinamidine synthetase
1
pembrolizumab
1
ofatumumab
1
obinutuzumab
1
lortalamine
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Disease
×
Educational Status
×
Clear all
NCT05990270
2024-06-24
EEWCCKAB
Kahramanmaras Sutcu Imam University
Phase NA
Completed
102 enrolled